Staar Surgical ( (STAA) ) has provided an update.
On March 17, 2025, STAAR Surgical Company announced a realignment of its leadership structure to better address market needs and drive revenue growth. Warren Foust was promoted to President and Chief Operating Officer, while Magda Michna was appointed Chief Development Officer, taking on expanded responsibilities. Deborah Andrews returned as Interim Chief Financial Officer, replacing Patrick Williams, who stepped down. The changes aim to streamline operations, improve cost structure, and enhance shareholder value.
More about Staar Surgical
STAAR Surgical Company, headquartered in Lake Forest, CA, is a leader in ophthalmic surgery, specializing in the design, development, manufacturing, and marketing of implantable lenses for vision correction. Their flagship product, the Implantable Collamer Lens (ICL), is used in refractive surgery and marketed in over 75 countries.
YTD Price Performance: -26.91%
Average Trading Volume: 1,030,255
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $841M
Learn more about STAA stock on TipRanks’ Stock Analysis page.